These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10772376)

  • 1. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
    Najib MM; Stein GE; Goss TF
    Pharmacotherapy; 2000 Apr; 20(4):461-9. PubMed ID: 10772376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
    Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
    Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M; Lode H; Gialdroni-Grassi G; Huchon G; Hosie J; Legakis N; Regamey C; Segev S; Vester R; Wijnands WJ; Tolstuchow N
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia.
    Paladino JA; Gudgel LD; Forrest A; Niederman MS
    Chest; 2002 Oct; 122(4):1271-9. PubMed ID: 12377852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
    Donowitz GR; Brandon ML; Salisbury JP; Harman CP; Tipping DM; Urick AE; Talbot GH
    Clin Ther; 1997; 19(5):936-53. PubMed ID: 9385482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
    Dresser LD; Niederman MS; Paladino JA
    Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sparfloxacin: a review.
    Schentag JJ
    Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
    Ramirez J; Unowsky J; Talbot GH; Zhang H; Townsend L
    Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
    Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin versus erythromycin for community-acquired pneumonia: a cost-minimization analysis.
    Howard KB; Blumenschein K; Rapp RP
    Am J Health Syst Pharm; 1999 Aug; 56(15):1521-4. PubMed ID: 10478989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.
    Lode H; Garau J; Grassi C; Hosie J; Huchon G; Legakis N; Segev S; Wijnands G
    Eur Respir J; 1995 Dec; 8(12):1999-2007. PubMed ID: 8666093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children.
    Aurangzeb B; Hameed A
    J Coll Physicians Surg Pak; 2003 Dec; 13(12):704-7. PubMed ID: 15569557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
    Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
    Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin].
    Rubio-Terrés C; Cots JM; Domínguez-Gil A; Herreras A; Sánchez Gascón F; Chang J; Trilla A
    Rev Esp Quimioter; 2003 Sep; 16(3):295-303. PubMed ID: 14702121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
    Stein GE; Mantz SL
    Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.